

Global Biologics Market: Drivers, Opportunities, Trends, and Forecasts 2018-2024

<https://marketpublishers.com/r/G1FB44B0742EN.html>

Date: May 2018

Pages: 121

Price: US\$ 3,500.00 (Single User License)

ID: G1FB44B0742EN

Abstracts

Global Biologics Market – Drivers, Opportunities, Trends, and Forecasts: 2018–2024

Overview: Biologics drugs are complex molecules that are manufactured from living organisms or components of living organisms. Biologics include a wide variety of products derived from human, animal, or microorganisms by using biotechnological processes. Many biologics are produced using recombinant DNA technology. They are sometimes referred to as biopharmaceuticals or biological drugs. Various types of biologic drugs include monoclonal antibody, recombinant proteins/hormones, vaccines, cell and gene therapy and others. These biologics may contain proteins that control the action of other proteins and cellular processes, genes that control production of vital proteins, modified human hormones, or cells that produce substances that suppress or activate components of the immune system. Biologics are sometimes referred as referred to as biologic response modifiers, as they change the manner of operation of natural biologic intracellular and cellular actions.

The market for biologics is driven by increasing incidence of disease across the globe, increasing number of biologics approvals and emergence of next generation biologics such as cell and gene therapy. Strong pipelined products and huge number of ongoing clinical trials are providing market growth opportunity. Challenges associated with biologics production, high cost of the drug, increasing number of biologics going off patent and emergence of biosimilars are hampering market growth.

Market Analysis: The “Global Biologics market” is estimated to witness a CAGR of 9.9% during the forecast period 2018–2024. The global market is analyzed based on three segments – Product, Application and regions.

Regional Analysis: The regions covered in the report are the North America, Europe, Asia Pacific, and Rest of the World (ROW). North America is the major shareholder in the global biologics market, followed by Europe. North America dominates the biologics market due to increasing product approvals, increasing demand for the product to treat various disease conditions, and presence of established players in this region. Asia-Pacific region is expected to have the fastest growth rate during the forecasted period due to increasing research activities, flexible regulatory environment for clinical trials, growing awareness about biopharmaceutical therapeutics, and rising healthcare expenditure.

Product Analysis: The market by product is segmented into monoclonal antibodies, recombinant proteins/hormones, vaccines, cell and gene therapy and others. Monoclonal antibodies occupied major market share of global biologics market in 2017 and cell and gene therapy is expected to grow at high CAGR during the forecasted period. Wide application of monoclonal antibodies in treatment of various diseases makes this segment, a major shareholder of biologics products market.

Application Analysis: The market by application is segmented into cancer, infectious disease, immunological disorders, hematological disorders, cardiovascular disease and others. Among various application, cancer occupied the largest share in 2017 and is expected to grow at fastest rate during the forecasted period. Growing elderly population, changing lifestyle, increasing disease prevalence makes cancer, the fastest growing application segment during the forecasted period.

Key Players: F. Hoffmann-La Roche, Amgen, Inc., Sanofi S.A., Novo Nordisk A/S, Johnson and Johnson, AbbVie, Inc., Novartis AG, GlaxoSmithKline plc, Bristol-Myers Squibb, Merck & Co., Eli Lilly & Company Ltd., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company and other predominate and niche players.

Competitive Analysis: Currently cancer segment dominates the global biologics segment. Biologics are entering new therapeutic areas such as, asthma and allergy where they are not present historically. The key market players are taking the advantage of strategic deals and product approvals to increase their share in the market. For instance, in September 2017, GSK and AbCellera Biologics, Inc. entered an antibody discovery research collaboration, for the discovery of monoclonal antibodies against an undisclosed membrane protein target. In August 2017, Novartis received first FDA approval from FDA for CAR-T cell therapy, Kymriah to treat patients with B-cell precursor acute lymphoblastic leukemia (ALL) and in May 2018, Novartis received

second FDA approval for Kymriah to treat patients with B-cell lymphoma.

Benefits: The report provides complete details about the usage and adoption rate of biologics in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player's initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Contents

1 INDUSTRY OUTLOOK

- 1.1 Industry Overview
- 1.2 Industry Trends
 - 1.2.1 R&D pipeline in pharmaceutical industry
 - 1.2.2 Top pharma drugs by sales in 2017 (\$Million)

2 REPORT OUTLINE

- 2.1 Report Scope
- 2.2 Report Summary
- 2.3 Research Methodology
- 2.4 Report Assumptions

3 MARKET SNAPSHOT

- 3.1 Market Definition – Infoholic Research
- 3.2 Biologics patent expiration in US and Europe (2010-2020)
- 3.3 Segmented Addressable Market (SAM)
- 3.4 Trends of the biologics market
- 3.5 Related Markets
 - 3.5.1 Over the counter drugs
 - 3.5.2 Orphan drugs
 - 3.5.3 Human Insulin

4 MARKET OUTLOOK

- 4.1 Market segmentation
- 4.2 PEST Analysis
- 4.3 Porter 5(Five) Forces

5 MARKET CHARACTERISTICS

- 5.1 DRO – Global Biologics Market Dynamics
 - 5.1.1 Drivers
 - 5.1.1.1 Growing incidence of disease across the globe
 - 5.1.1.2 Increasing number of biologics approvals

5.1.2 Opportunities

5.1.2.1 Strong portfolio of product pipeline and huge number of ongoing clinical trials

5.1.2.2 Increasing opportunities in emerging markets

5.1.3 Restraints

5.1.3.1 Challenges associated with biologics production

5.1.3.2 Increasing number of biologics going off patent and emergence of biosimilars

5.2 DRO – Impact Analysis

5.3 Key Stakeholders

6 PRODUCTS: MARKET SIZE & ANALYSIS

6.1 Overview

6.2 Monoclonal antibodies

6.3 Recombinant proteins/Hormones

6.4 Vaccines

6.5 Cell and Gene Therapy

6.6 Others

7 APPLICATIONS: MARKET SIZE & ANALYSIS

7.1 Overview

7.2 Cancer

7.3 Immunological disorders

7.4 Infectious disease

7.5 Hematologic disorders

7.6 Cardiovascular disease

7.7 Others

8 REGIONS: MARKET SIZE AND ANALYSIS

8.1 Overview

8.2 North America

8.2.1 US

8.2.2 Canada

8.3 Europe

8.3.1 UK

8.3.2 Germany

8.3.3 France

8.3.4 Spain

8.4 Asia Pacific

8.4.1 India

8.4.2 China

8.4.3 Japan

8.5 Rest of the World

9 COMPETITIVE LANDSCAPE

9.1 Overview

10 VENDOR PROFILES

10.1 F .Hoffmann-La Roche

10.1.1 Overview

10.1.2 Business Unit

10.1.3 Geographic Presence

10.1.4 Business Focus

10.1.5 SWOT Analysis

10.1.6 Business Strategy

10.2 Sanofi S.A

10.2.1 Overview

10.2.2 Business Units

10.2.3 Geographic Presence

10.2.4 Business Focus

10.2.5 SWOT Analysis

10.2.6 Business Strategies

10.3 Amgen Inc

10.3.1 Overview

10.3.2 Geographic Presence

10.3.3 Business Focus

10.3.4 SWOT Analysis

10.3.5 Business Strategies

10.4 Novo Nordisk A/S

10.4.1 Overview

10.4.2 Business Units

10.4.3 Geographic Presence

10.4.4 Business Focus

10.4.5 SWOT Analysis

10.4.6 Business Strategies

- 10.5 AbbVie Inc
 - 10.5.1 Overview
 - 10.5.2 Geographic Presence
 - 10.5.3 Business Focus
 - 10.5.4 SWOT Analysis
 - 10.5.5 Business Strategies
- 10.6 Johnson & Johnson
 - 10.6.1 Overview
 - 10.6.2 Business Units
 - 10.6.3 Geographic Revenue
 - 10.6.4 Business Focus
 - 10.6.5 SWOT Analysis
 - 10.6.6 Business Strategies
- 10.7 Novartis AG
 - 10.7.1 Overview
 - 10.7.2 Business Units
 - 10.7.3 Geographic Revenue
 - 10.7.4 Business Focus
 - 10.7.5 SWOT Analysis
 - 10.7.6 Business Strategies

11 COMPANIES TO WATCH FOR

- 11.1 Bristol-Myers Squibb
 - 11.1.1 Overview
- 11.2 GlaxoSmithKline plc
 - 11.2.1 Overview
- 11.3 Merck & Co
 - 11.3.1 Overview
- 11.4 Eli Lilly and Company Ltd
 - 11.4.1 Overview
- 11.5 Teva Pharmaceutical Industries Ltd
 - 11.5.1 Overview
- 11.6 AstraZeneca PLC
 - 11.6.1 Overview
- 11.7 Takeda pharmaceuticals
 - 11.7.1 Overview

Annexure

Acronyms

List Of Tables

LIST OF TABLES

- Table 1 PHARMA DRUGS BY SALES, 2017
- Table 2 GLOBAL BIOLOGICS MARKET REVENUE BY REGIONS, 2017–2024 (\$MILLION)
- Table 3 OTHER PROMINENT VENDORS OF BIOLOGICS MARKET
- Table 4 F .HOFFMANN-LA ROCHE: OFFERINGS
- Table 5 F .HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS
- Table 6 SANOFI.: OFFERINGS
- Table 7 SANOFI: RECENT DEVELOPMENTS
- Table 8 AMGEN INC.: OFFERINGS
- Table 9 AMGEN INC.: RECENT DEVELOPMENTS
- Table 10 NOVO NORDISK A/S: OFFERINGS
- Table 11 NOVO NORDISK A/S: RECENT DEVELOPMENTS
- Table 12 ABBVIE INC.: OFFERINGS
- Table 13 ABBVIE INC: RECENT DEVELOPMENTS
- Table 14 JOHNSON & JOHNSON: PRODUCT OFFERINGS
- Table 15 JOHNSON & JOHNSON: RECENT DEVELOPMENTS
- Table 16 NOVARTIS AG: PRODUCT OFFERINGS
- Table 17 NOVARTIS AG: RECENT DEVELOPMENTS
- Table 18 NOVARTIS AG: OVERVIEW SNAPSHOT
- Table 19 BRISTOL-MYERS SQUIBB: SNAPSHOT
- Table 20 BRISTOL-MYERS SQUIBB: RECENT DEVELOPMENTS
- Table 21 GLAXOSMITHKLINE PLC.: OVERVIEW
- Table 22 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
- Table 23 MERCK & CO: OVERVIEW
- Table 24 MERCK & CO: RECENT DEVELOPMENTS
- Table 25 ELI LILLY AND COMPANY: SNAPSHOT
- Table 26 ELI LILLY AND COMPANY: RECENT DEVELOPMENTS
- Table 27 TEVA PHARMACEUTICAL INDUSTRIES LTD.: OVERVIEW
- Table 28 TEVA PHARMACEUTICAL: RECENT DEVELOPMENTS
- Table 29 ASTRAZENECA PLC: SNAPSHOT
- Table 30 ASTRAZENECA PLC: RECENT DEVELOPMENTS
- Table 31 TAKEDA PHARMACEUTICALS: SNAPSHOT
- Table 32 TAKEDA PHARMACEUTICALS: RECENT DEVELOPMENTS

List Of Charts

LIST OF CHARTS

- Chart 1 GLOBAL PHARMACEUTICAL R&D SPENDING (2010-2016)
- Chart 2 PHARMACEUTICAL MOLECULES IN DEVELOPMENT FOR NON-COMMUNICABLE DISEASES (NCDS)
- Chart 3 R&D INVESTMENT BY TOP 10 COMPANIES (\$BN)
- Chart 4 PHARMACEUTICAL DRUGS BY SALES, 2017
- Chart 5 RESEARCH METHODOLOGY OF GLOBAL BIOLOGICS MARKET
- Chart 6 GLOBAL BIOLOGICS MARKET REVENUE, 2017–2024 (\$MILLION)
- Chart 7 SEGMENTATION OF GLOBAL BIOLOGICS MARKET
- Chart 8 PEST ANALYSIS OF GLOBAL BIOLOGICS MARKET
- Chart 9 PORTER 5 FORCES ON GLOBAL BIOLOGICS MARKET
- Chart 10 DRO – IMPACT ANALYSIS OF GLOBAL BIOLOGICS MARKET
- Chart 11 KEY STAKEHOLDERS
- Chart 12 GLOBAL BIOLOGICS BY PRODUCT SEGMENTATION, 2017 (%)
- Chart 13 GLOBAL MONOCLONAL ANTIBODY MARKET FORECAST, 2017–2024 (\$MILLION)
- Chart 14 GLOBAL RECOMBINANT PROTEIN/HORMONES MARKET FORECAST, 2017–2024 (\$MILLION)
- Chart 15 GLOBAL VACCINES MARKET FORECAST, 2017–2024 (\$MILLION)
- Chart 16 GLOBAL CELL AND GENE THERAPY MARKET FORECAST, 2017–2024 (\$MILLION)
- Chart 17 GLOBAL CELL AND GENE THERAPY MARKET FORECAST, 2017–2024 (\$MILLION)
- Chart 18 GLOBAL BIOLOGICS MARKET BY APPLICATION SEGMENTATION, 2017 (%)
- Chart 19 GLOBAL BIOLOGICS MARKET BY GEOGRAPHICAL SEGMENTATION, 2017 (%)
- Chart 20 BIOLOGICS MARKET REVENUE IN NORTH AMERICA, 2017–2024 (\$MILLION)
- Chart 21 BIOLOGICS MARKET REVENUE IN EUROPE, 2017–2024 (\$MILLION)
- Chart 22 BIOLOGICS MARKET REVENUE IN ASIA PACIFIC, 2017–2024 (\$MILLION)
- Chart 23 BIOLOGICS MARKET REVENUE IN REST OF THE WORLD, 2017–2024 (\$MILLION)
- Chart 24 F .HOFFMANN-LA ROCHE: OVERVIEW SNAPSHOT
- Chart 25 F .HOFFMANN.LA ROCHE: BUSINESS UNITS
- Chart 26 F .HOFFMANN-LA ROCHE: GEOGRAPHICAL PRESENCE

- Chart 27 F .HOFFMANN-LA ROCHE: SWOT ANALYSIS
- Chart 28 SANOFI: OVERVIEW SNAPSHOT
- Chart 29 SANOFI SA: BUSINESS UNITS
- Chart 30 SANOFI SA: GEOGRAPHIC PRESENCE
- Chart 31 SANOFI SA: SWOT ANALYSIS
- Chart 32 AMGEN INC.: OVERVIEW SNAPSHOT
- Chart 33 AMGEN INC.: GEOGRAPHIC PRESENCE
- Chart 34 AMGEN INC: SWOT ANALYSIS
- Chart 35 NOVO NORDISK: OVERVIEW SNAPSHOT
- Chart 36 NOVO NORDISK: BUSINESS UNITS
- Chart 37 NOVO NORDISK: GEOGRAPHIC PRESENCE
- Chart 38 NOVO NORDISK A/S: SWOT ANALYSIS
- Chart 39 ABBVIEE INC: OVERVIEW SNAPSHOT
- Chart 40 ABBVIEE INC.: GEOGRAPHIC PRESENCE
- Chart 41 ABBVIE INC.: SWOT ANALYSIS
- Chart 42 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT
- Chart 43 JOHNSON & JOHNSON: BUSINESS UNITS
- Chart 44 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE
- Chart 45 JOHNSON & JOHNSON: SWOT ANALYSIS
- Chart 46 NOVARTIS AG: BUSINESS UNITS
- Chart 47 NOVARTIS AG: GEOGRAPHIC REVENUE
- Chart 48 NOVARTIS AG: SWOT ANALYSIS

I would like to order

Product name: Global Biologics Market: Drivers, Opportunities, Trends, and Forecasts 2018-2024

Product link: <https://marketpublishers.com/r/G1FB44B0742EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G1FB44B0742EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970